Case Report

Metabolic complete response after docetaxel, cisplatin and S-1 (DCS) therapy and sequential radiation therapy in a patient with anal squamous cell carcinoma: a case report

Shutaro Oiwa1, Toshizo Takayama1, Masahiro Yoshida2, Naoka Okamura1, Junko Sugiyama1, Michiaki Hirayama2, Daisuke Sato3, Shuji Kitashiro3, Shunichi Okushiba3 and Yasushi Tsuji1*

1Department of Medical Oncology, Tonan Hospital, Sapporo, Japan
2Department of Gastroenterology, Tonan Hospital, Sapporo, Japan
3Department of Surgery, Tonan Hospital, Sapporo, Japan

ARTICLE INFO

Article history:
Received 18 April, 2018
Accepted 30 April, 2018
Published 6 May 2018

ABSTRACT

Chemoradiotherapy is the standard treatment for anal squamous cell carcinoma (SCC). Recently, it has been reported that a combination therapy of taxane, platinum and fluoride pyrimidine is useful for SCC. A 58-year-old woman was admitted to our hospital with anal pain and constipation. Computed tomography (CT) scan revealed a 9×6 cm tumor, stenosis in the anal region, and swollen pelvic and inguinal lymph nodes. She underwent laparoscopic ileal stomatoplasty and biopsy. A diagnosis of SCC of anal canal was confirmed by histopathological examination. She received a combination therapy with docetaxel, cisplatin and S-1 (DCS), followed by radiation therapy (RT). After her chemoradiotherapy, no abnormal accumulation was observed on a positron emission tomography-computed tomography (PET-CT) scan, and she was diagnosed with metabolic complete response (CR). The 3-drug combination therapy of taxane, platinum, fluoride pyrimidine followed by RT as primary treatment may be effective in the treatment of anal SCC.

© 2018 Yasushi Tsuji. Hosting by Science Repository. All rights reserved.

Introduction

Anal squamous cell carcinoma is a relatively rare disease, representing only 1-5% of all gastrointestinal malignancies [1, 2]. There is no established treatment regimen in Japan, although chemoradiotherapy is the standard treatment in Western countries [3, 4]. Recently, it has been reported that a combination therapy of taxane, platinum and fluoride pyrimidine is effective in the treatment of squamous cell carcinoma, for example esophageal cancer [5, 6]. We report here a case of anal squamous cell carcinoma with docetaxel, cisplatin and S-1 (DCS) therapy and sequential radiation therapy (RT) as primary treatment.

Case

A 58-year-old woman was admitted to our hospital with anal pain and constipation. She had been in her usual state of health until about 10 months before admission, when a lump in her anal region was found.
months before admission, she developed progressive pain and started to bleed anally. One month before admission she saw her primary physician because she suffered from constipation and her symptoms were progressing. She was diagnosed with a tumor in the anal region and referred to our hospital for further evaluation. Her past medical history and family history was not contributory. On physical examination, her height was 166 cm, her body weight was 49 kg. Her consciousness was unimpaired, her body temperature was 36.5℃, her blood pressure was 147/61 mmHg, her pulse was 64/min and regular. There was no jaundice. Cervical and supravacular lymph nodes were not palpable. Her lung examination was clear. Heart examination was unremarkable with normal S1 and S2, no murmur. Her abdomen was soft, flat and nontender. Digital rectal examination revealed a tumor involving the entire anal canal with protruding perianal component.

Hematologic parameters were as follows: Red blood cell count was 305×10⁴/μg, hemoglobin was 7.9 g/dl, hematocrit was 25.9%, leukocyte count was 7210/μl, platelet count was 33x10⁴/μl. Blood chemistry and serologic findings were almost completely within normal limits, except for C-reactive protein (2.3mg/dl), carcinoembryonic antigen (CEA) (9.5ng/ml, normal range<5 ng/ml) and squamous cell carcinoma-related antigen (SCC) (7.1ng/ml, normal range<1.5 ng/ml). HPV genotype test on cervical cytology was negative.

Contrast computed tomography (CT) scan revealed a 9 × 6 cm tumor and stenosis in the anal region. Inguinal lymph nodes were swollen (Fig1A-C).

Rectal or anal canal cancer was suspected, but local excision was deemed difficult. Therefore, the patient underwent laparoscopic ileal stomatoplasty. At the same time, trans-anal tumor biopsy was performed. A diagnosis of squamous cell carcinoma of anal canal was confirmed by histological examination. Chemotherapy and sequential RT was indicated because the tumor was very large and lymph nodes were swollen in the pelvis.

After 1-month post admission, she received DCS therapy (docetaxel: 60mg/m², given on day 8, cisplatin: 60mg/m², given on day 8, S-1: 120mg/day, given on days 1-14, every 3 weeks). During the first cycle, she developed a grade 2 diarrhea, nausea and vomiting. In response to the treatment, CEA and SCC decreased quickly. Radiotherapy was administered to the primary tumor and to pelvic and inguinal lymph nodes (36 Gy in 20 fractions and 21.6 Gy in 12 fractions), because she responded well to DCS therapy. Lower gastrointestinal endoscopy after chemoradiotherapy showed only a scar in the anal canal and an ulcer in the rectum (Fig2). There was no carcinoma on biopsy of that region. Contrast CT scan after chemoradiotherapy revealed that wall thickening and lymph nodes swelling disappeared (Fig3). In positron emission tomography-computed tomography (PET-CT) scan after chemoradiotherapy, abnormal accumulation was not observed, and she was diagnosed with metabolic complete response (CR) (Fig4). After chemoradiotherapy, she was administrated S-1 (80 mg/day, given on days 1-14, every 3 weeks) for 6 months. No malignant findings or lymph node enlargement was observed on magnetic resonance imaging (MRI) scan of the pelvic cavity after the completion of S-1 therapy (Fig5). Tumor markers have not increased again although S-1 was discontinued.

**Figures**

1. Figure 1
2. Figure 2
3. Figure 3
4. Figure 4
trial of chemoradiotherapy concurrent with S-1 plus mitomycin C in patients with clinical stage II/III squamous cell carcinoma of anal canal is ongoing [9]. Japanese case reports indicate that cisplatin and 5-FU, mitomycin C and S-1, cisplatin and S-1 with RT are effective [10, 11].

A combination therapy with taxane, platinum, fluoro pyrimidine has been reported effective in the treatment of esophageal squamous cell carcinoma, head and neck squamous cell carcinoma and other SCC tumors [5, 6]. In Japan, the efficacy of DCS therapy for SCC is being investigated as well [12]. Kim et al. reported the usefulness of docetaxel, cisplatin and 5-FU (DCF) therapy in 8 patients with recurrent anal SCC after chemoradiotherapy. The overall survival rate at 12 months was 62.5% [13]. Now a phase II study is ongoing [14].

In this case, DCS therapy followed by RT therapy as primary treatment was effective in the treatment of anal SCC. The 3-drug combination therapy of taxane, platinum, fluoro pyrimidine with RT as primary treatment may be useful in anal SCC treatment although an accumulation and analysis of more data is necessary for confirmation.

Conclusion

We reported a patient with anal canal cancer who received DCS therapy and sequential RT as primary treatment and was diagnosed with metabolic CR in PET-CT as a result.

REFERENCES

1. National Cancer Institute. SEER cancer statistics factsheets: anal cancer. Accessed 2 March 2018.
2. Julie DR, Goodman KA (2016) Advances in the Management of Anal Cancer. Curr Oncol Rep 18: 20-12.
3. Benson AB III, Venook AP, Bekail-Saab T, Chan E, Chen Y-J. Anal carcinoma, version2: 2017: featured updates to the NCCN guidelines. Accessed 2 March 2018.
4. Takashima A, Shimada Y, Hamaguchi T, Ito Y, Masaki T, et al. (2009) Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol 14: 416-420. [Crossref]
5. Hironaka S, Tsubosa Y, Mizusawa J, Kii T, Kato K, et al. (2014) Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci 105: 1189-1195. [Crossref]
6. Posner MR, Herschok DM, Blajman CR, Mickiewicz E, Winquist E et al. (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357: 1705-1715. [Crossref]
7. Sameshima S, Sawada T, Nagasako K (2005) Squamous cell carcinoma of anus and carcinoma in association with anal fistula in Japan, multi-institutional registration. J Jpn Soc Coloproctol 41: 415-421.
8. Watanabe T, Muro K, Ajioka Y, Hashiguchi T, Ito Y, et al. (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23:1-34. [Crossref]
9. Takashima A, Shimada Y, Hamaguchi T, Ito Y, Nakano A, et al. (2011) A Phase I/II Trial of Chemoradiotherapy Concurrent with S-1 plus Mitomycin C in Patients with Clinical Stage II/III Squamous Cell Carcinoma of Anal Canal (JCOG0803: SMART-AC). Jpn J Clin Oncol 41: 713-717. [Crossref]
10. Someo Y, Ishikawa T, Iwata N, Takahashi, Kikuchi A, et al. (2014) Three cases of Anal Squamous Cell Carcinoma Treated with Chemoradiotherapy. Gan To Kagaku Ryoho 41: 1855-1857. [Crossref]
11. Miyamoto S, Maeda Y, Hishima T, Sasaki T (2009) Case of higher efficacy by chemoradiotherapy for anal canal cancer from left cervix metastases to lymph nodes. *Jpn J Cancer Chemother* 36: 329-332.

12. Uemura N, Kikuchi S, Sato Y, Ohnuma H, Okamoto K, et al. (2017) A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer. *Cancer Chemother Pharmacol* 80: 707-713. [Crossref]

13. S Kim, M Jury, L Mansi, B Benzidane, A Cazorla, et al. (2013) DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. *Ann Oncol* 24: 3045-3050. [Crossref]

14. S Kim, M Jury, T André, V Vendrely, B Buecher, et al. (2017) Docetaxel, Cisplatin, and 5-fluorouracil(DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma : a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). *BMC Cancer* 17: 574. [Crossref]